Shuttle Pharmaceuticals Expands Phase 2 Glioblastoma Trial with Two Additional Sites

Shuttle Pharmaceuticals Holdings, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients tr...

September 17, 2024 | Tuesday | News
Vivtex and Equillium Partner to Advance Oral Formulation of Novel GI Inflammation Therapy

Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therap...

September 17, 2024 | Tuesday | News
FDA Approves Roche’s OCREVUS ZUNOVO™ for Subcutaneous MS Treatment, Expanding Access for Patients

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's off...

September 16, 2024 | Monday | News
FDA Grants Seven Years of Market Exclusivity to YORVIPATH for Treating Hypoparathyroidism in Adults

U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in...

September 12, 2024 | Thursday | News
FDA Approves TREMFYA® as First Dual-Acting Interleukin-23 Inhibitor for Ulcerative Colitis Treatment

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically signifi...

September 12, 2024 | Thursday | News
Zoetis Expands India Capability Center in Hyderabad, Strengthening City’s Role in Global HealthTech

Zoetis, the world’s largest animal health company, has marked another milestone in Hyderabad's thriving life sciences and healthtech ecosystem by e...

September 11, 2024 | Wednesday | News
Oneness Biotech and Microbio's Pan-COVID Drug SNS812 Achieves Key Phase 2 Trial Success, Showing Broad-Spectrum Efficacy

Oneness Biotech and Microbio (Shanghai) announced that the pan-COVID New Drug, SNS812, co-developed by both companies achieves statistical significance wit...

September 11, 2024 | Wednesday | News
Gilead and Genesis Partner to Leverage GEMS AI Platform for Small Molecule Drug Discovery

Gilead and Genesis Will Leverage the GEMS AI Platform to Generate and Jointly Optimize Molecules Against Selected Targets -- -- Gilead Receives Exclus...

September 11, 2024 | Wednesday | News
Hongene Biotech and ReciBioPharm Forge Strategic Alliance to Enhance Gene Editing Drug Manufacturing

Hongene Biotech Corporation, a global leader in nucleic acid manufacturing, and ReciBioPharm, a leading advanced therapeutics CDMO services provider, hav...

September 09, 2024 | Monday | News
Sun Pharma and Moebius Medical Receive FDA Fast Track Designation for Osteoarthritis Treatment MM-II

Sun Pharma and Israel-based Moebius Medical Limited announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) t...

September 09, 2024 | Monday | News
Guardant Health Japan Receives MHLW Approval for First Blood-Based Diagnostic Test for EGFR Exon 20 Insertion Mutations in NSCLC

Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncology company, announced that the M...

September 03, 2024 | Tuesday | News
Johnson & Johnson Submits First Global Application for Nipocalimab, Pioneering Treatment for Generalized Myasthenia Gravis

Johnson & Johnson  announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for nipocali...

August 30, 2024 | Friday | News
Celltrion USA Expands Patient Access to ZYMFENTRA® Through Agreement with Cigna and Express Scripts

Celltrion USA announced that it has signed an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the p...

August 29, 2024 | Thursday | News
GSK's Nucala Becomes First and Only Biologic Approved in Japan for CRSwNP with Four-Weekly Dosing Schedule

Nucala is the first and only biologic in Japan with a four-weekly dosing schedule for this condition Chronic rhinosinusitis with nasal polyps (CRSwNP)...

August 29, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close